Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(Forbes) Apr 27, 2017 - Today the FDA approved a new drug—one of few available—for treating liver cancer. Regorafenib is a pill manufactured by Bayer and sold as Stivarga. Already it’s been approved for use in some patients with refractory colon, rectal, and GI stromal tumors.
(U.S. News & World Report/HealthDay News) Apr 26, 2017 - Children given an organ transplant have a substantially higher risk of developing cancer -- in some cases up to 200 times higher -- than the general population, a new study finds.
(The Economist) May 4, 2017 - AstraZeneca’s Imfinzi costs $180,000 for a year’s treatment.
(USA Today) May 5, 2017 - A Missouri jury ordered health products giant Johnson & Johnson to pay more than $110 million to a Virginia woman for allegedly failing to disclose the cancer risk from its baby powder and another product.
(New York Times/Well blog) May 8, 2017 - Fear of breast cancer is widespread, yet many women don’t realize that could counter their concern by adopting protective living habits to help keep breast cancer at bay. The habits described below may also help to ward off other life-threatening ills, like heart disease and diabetes.
(Forbes) May 11, 2017 - Merck–and its cancer drug Keytruda–had a great day yesterday.
(TheStreet) May 8, 2017 - Shares of Kite Pharma fell Monday due to the death of a cancer patient from brain swelling following treatment with the company's CAR-T therapy KTE-C19.
(New York Times/Well blog) May 14, 2017 - A rare cancer of the immune system, linked to implants, has had devastating effects on women, many of whom had reconstructive surgery after breast cancer.
(AstraZeneca) May 12, 2017 - Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis; Imfinzi is the first immuno-oncology medicine to show superior PFS in this setting; plans for regulatory submission under active discussion with authorities.
(Rare Disease Report) Apr 29, 2017 - On Friday evening, Takeda Pharmaceuticals announced the FDA has approved Alunbrig (brigatinib) to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.